TY - JOUR T1 - Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure JF - Evidence Based Medicine JO - Evid Based Med SP - 14 LP - 14 DO - 10.1136/ebm.9.1.14 VL - 9 IS - 1 A2 - , Y1 - 2004/01/01 UR - http://ebm.bmj.com/content/9/1/14.abstract N2 - Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with chronic heart failure (CHF), what is the comparative effectiveness of carvedilol and metoprolol tartrate on morbidity and mortality? Clinical impact ratings Internal medicine ★★★★★★☆ IM/Ambulatory ★★★★★★☆ Cardiology ★★★★★★☆ Design: randomised controlled trial (Carvedilol Or Metoprolol European Trial [COMET]). Allocation: {concealed*}†. Blinding: blinded {patients, healthcare providers, data collectors, outcome assessors, data analysts, data safety and monitoring committee, and manuscript writers}†.* Follow up period: mean 58 months. Setting: 341 centres in 15 European countries. Patients: 3029 patients (mean age 62 y, 80% men, 99% white) with symptomatic CHF and left ventricular ejection fraction ⩽0.35. Patients had ⩾1 cardiovascular admission in the previous 2 years and were on stable heart failure treatment with angiotensin converting enzyme inhibitors for ⩾4 weeks and treatment … ER -